| CAS NO: | 396-01-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 250mg | 询价 |
| 500mg | 询价 |
| 1g | 询价 |
| 2g | 询价 |
| 5g | 询价 |
| 10g | 询价 |
| Molecular Weight (MW) | 253.26 |
|---|---|
| Formula | C12H11N7 |
| CAS No. | 396-01-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 20 mg/mL (79 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | 0.5% CMC Na+1% Tween 80: 30 mg/mL |
| Synonyms | SKF-8542; BRN 0266723; SKF 8542; BRN0266723; SKF8542; BRN-0266723; Triamterene; Diucelpin; Diurene |
| In Vitro | In vitro activity: Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. Triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion. |
|---|---|
| In Vivo | 4'-hydroxylation of triamterene in humans appears to be mediated exclusively by CYP1A2. Inhibition or induction of CYP1A2 will change the time course of both triamterene and its active phase-II metabolite. |
| Animal model | |
| Formulation & Dosage | |
| References | Mol Pharmacol. 2003 Oct;64(4):848-56; Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2026 |
